Original Publication Date: 1 March, 2017
Publication / Source: Melanoma Management
Authors: Justine V Cohen & Ryan J Sullivan
Unprecedented responses to newly available treatments for metastatic melanoma have dramatically changed the therapeutic landscape of this disease during the last decade, highlighted by eight new US FDA approved therapies since 2011. Two approaches include modulation of the immune system with checkpoint inhibitors and targeting oncogenic drivers of melanoma using BRAF and MEK inhibitors (BRAFi and MEKi). As these therapies show more promise, the number of clinical trials exploring various combinations continues to increase.